Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (572)	4/8/2004 8:42:53 AM
From: Icebrg	Respond to of 1022

Lilly to Evaluate GlycoFi's Glycoprotein Production Platform Thursday April 8, 8:31 am ET LEBANON, N.H.--(BUSINESS WIRE)--April 8, 2004--GlycoFi, Inc. announces the initiation of a joint research study to evaluate GlycoFi's yeast-based platform for the production of an undisclosed protein. The study, supported by Eli Lilly and Company, will combine GlycoFi's unique expression technology to produce human glycoproteins with Lilly's expertise in the area of therapeutic protein discovery and commercialization. About GlycoFi GlycoFi, Inc. is the industry leader for the engineering and production of therapeutic glycoproteins in yeast systems. The company was founded in 2000 with the mission to be a leading biotechnology company in the development, manufacturing, and commercialization of biotherapeutics. The company has engineered yeast and other fungal protein expression systems to produce fully humanized glycoproteins, thus greatly increasing the efficiency, fidelity and scalability at which those proteins can be made. For more information, please visit www.glycofi.com.